INmune BioINMB
INMB
About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Employees: 13
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
100% more call options, than puts
Call options by funds: $3.07M | Put options by funds: $1.54M
61% more capital invested
Capital invested by funds: $28.8M [Q4 2024] → $46.3M (+$17.5M) [Q1 2025]
13% more funds holding
Funds holding: 71 [Q4 2024] → 80 (+9) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
1.98% less ownership
Funds ownership: 27.83% [Q4 2024] → 25.85% (-1.98%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$0.60
78%
downside
Avg. target
$4.30
60%
upside
High target
$8
199%
upside
2 analyst ratings
1 positive
50%
0 neutral
0%
1 negative
50%
Maxim Group Jason McCarthy | 199%upside $8 | Buy Maintained | 2 Jul 2025 |
Scotiabank George Farmer | 78%downside $0.60 | Sector Underperform Downgraded | 1 Jul 2025 |
Financial journalist opinion
Based on 3 articles about INMB published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on the company's YouTube Channel following the conclusion of Alzheimer's Association International Conference (AAIC) in Toronto, Canada.
Neutral
Seeking Alpha
3 weeks ago
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's
INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see significant upside from XPro and CORDStrom, with blockbuster potential if approved, given INMB's tiny current market cap. Risks include uncertain XPro efficacy, need for more capital, and dilution; I maintain a 2/5 conviction rating and keep INMB in my speculative portfolio.
Negative
Benzinga
3 weeks ago
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.
Neutral
GlobeNewsWire
1 month ago
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.
Negative
Proactive Investors
1 month ago
INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trial
INmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary cognitive endpoint in the overall intent-to-treat population, meaning it did not significantly improve cognitive function over six months compared to placebo in early Alzheimer's patients.
Negative
Benzinga
1 month ago
Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain
INmune Bio Inc. INMB stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro.
Negative
Reuters
1 month ago
INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study
INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares plunging nearly 59% in premarket trading.
Neutral
GlobeNewsWire
1 month ago
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro™ treatment over placebo was observed in cognitive, behavioral and biological endpoints.
Positive
Seeking Alpha
1 month ago
INmune Bio: Finding Pay Dirt In Alzheimer's?
INmune Bio is working on a drug for Alzheimer's, with a critical phase 2 readout to be announced. It is unclear whether this will be positive or negative. Other potential drug candidates could help pick up the slack if MINDFuL is a dud.
Neutral
GlobeNewsWire
1 month ago
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.
Charts implemented using Lightweight Charts™